Is this stuff dose dependent?
Will taking 500mg after a meal have 5 time the effect of 100mg or is there a limit?
Marks1972 wrote:Doesnt too much have a similar effect as a diabetic going low sugar?
health4ni wrote:I don't have a confirmed answer. But I think it is dose dependent. I think 200mg is twice as "powerful" as 100mg. I think.
julesm wrote:i think there is a lot of related questions over on anabolicminds regarding this matter- people asked the question of taking na-rala against P-slin (?) and the tissue specificity of each product.
Craig wrote:julesm wrote:i think there is a lot of related questions over on anabolicminds regarding this matter- people asked the question of taking na-rala against P-slin (?) and the tissue specificity of each product.
No real answer then![]()
I'm thinking of using it after dieting down to a low BF as part of a rebound cycle.
julesm wrote:i'd opt for the one that works through insulin dependent pathways- ie na-rala.
as regards dosage- i think it is dose dependant 100mg for every 40g of carbs (?) so it would be overkill to take 500mg if you only ingested 40g of carbs, plus you'd have a pretty horrendous hypo episode- headaches, nausea, faintness, tremors.
Abstract: Utilization of the insulin-signaling network in the metabolic actions of alpha-lipoic acid-reduction or oxidation?
ImmuneSupport.com
08-31-2005
Antioxid Redox Signal. 2005 Jul-Aug;7(7-8):1032-9.
Konrad D.
Division of Endocrinology and Diabetology, University Children's Hospital, Zurich, Switzerland. daniel.konrad@kispi.unizh.ch
Alpha-lipoic acid is a naturally occurring cofactor of mitochondrial dehydrogenase complexes and a potent antioxidant. It can interchange between a reduced form and an oxidized form, thereby displaying reducing (antioxidant) and prooxidant properties, respectively.
It is suggested that alpha-lipoic acid through its prooxidant properties acutely stimulates the insulin-signaling cascade, thereby increasing glucose uptake in muscle and fat cells. On the other hand, alpha-lipoic acid appears to protect the insulin-signaling cascade from oxidative stress-induced insulin resistance through its reducing capacities. In addition, alpha-lipoic acid seems to inhibit hepatic gluconeogenesis by interfering with fatty acid oxidation, as well as to increase peripheral glucose utilization by activating pyruvate dehydrogenase resulting in increased glucose oxidation. These different properties render alpha-lipoic acid a potentially attractive therapeutic agent for the treatment of insulin resistance.
Moreover, given the potential role of oxidative stress in the pathogenesis of secondary complications in diabetes, alpha-lipoic acid might be beneficial in the prevention/treatment of these complications as was recently shown for diabetic neuropathy.
PMID: 15998258 [PubMed - in process]
Users browsing this forum: Google [Bot], Rab and 22 guests